We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tristel Plc | LSE:TSTL | London | Ordinary Share | GB00B07RVT99 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
2.50 | 0.54% | 465.00 | 460.00 | 470.00 | 465.00 | 462.50 | 462.50 | 20,697 | 12:24:46 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 36.01M | 4.46M | 0.0941 | 49.42 | 220.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
25/4/2015 16:41 | Pity, I have an increase price at 70p :-( apad | apad | |
25/4/2015 16:40 | IC: Clean up with Tristel Each year, a staggering 300,000 NHS patients pick up infections while being treated at hospitals in England. Part of the NHS response to this has been to recommend the disinfectant products of Aim-traded Tristel (TSTL), which are now supplied to around 700 public and private hospitals in the UK. The company’s main technology is its patented chlorine dioxide formulation, a highly effective disinfectant that can kill C.difficile spores in 30 seconds. In addition to hospitals – which account for 86 per cent of turnover – Tristel’s sprays, gels, foams, liquids and other products are used to clean surfaces and instruments in pharmaceutical clean rooms and veterinary practices. A skin-friendly product has also been developed and is being rolled out, pending some regulatory hurdles. Tristel floated in 2005 and now boasts real sales momentum. It has generated record revenues in each of the past four six-month trading periods, and in the final half of 2014 grew sales by 15 per cent to £7.4m, in line with a sales goal of £20m by 2016-17. In the UK, which accounts for two-thirds of revenue, the key to sales growth is improving ties to hospitals’ infection control teams and targeting specialisations such as cardiology and ophthalmology, where adoption of Tristel’s products is less widespread. Increased scale has helped widen net margins, which are forecast to increase by 150 basis points to 15 per cent in the financial year to the end of June. This is leading to rapid EPS growth, which should also support forecasts of dividend increases. The shares should reward investors with a 3.8 per cent yield next year. And it’s not only the shares’ yield that represents attractive value. Tristel’s enterprise value is 12 times forecast operating profit, and 1.8 times this year’s expected sales. Based on these valuation measures, Tristel is valued at a discount to the sector of a quarter and a third, respectively. Part of the reason for this discount may be the company’s reliance on one main scientific area, and the risk posed if a new disinfectant technology supersedes Tristel’s brands. However, recurring revenues of 96 per cent should help to calm any nerves about the resilience of the business model, as should the fact that Tristel sells to more than 40 countries. One potentially game-changing country Tristel does not sell to at the moment is the US, despite considerable interest in the company’s products from clinicians across the pond. FDA approval of the company’s products could come within two to three years, according to analysts at Equity Development, providing access to the largest healthcare market in the world along with major potential for a re-rating of the shares. Management is understandably keen not to overplay the prospect of US expansion, although it remains a strategic priority, as does growth in Europe. In both cases, regulatory costs will eat into profits. But this is factored into the forecasts in our table and more than outweighed by the potential upside. Tristel’s shares have done well since 2013 and there is serious momentum in the growth story. The price-to-earnings-gr | apad | |
24/4/2015 08:27 | thank jimmy. Good news | gswredland | |
24/4/2015 08:07 | Reminder of the interim results: Financial highlights -- Revenue up 15% to GBP7.4m (2013: GBP6.4m) -- International sales up 26% to GBP2.4m (2013: GBP1.9m) -- Pre-tax profit before share based payments up 57% to GBP1.1m (2013: GBP0.7m) -- EBITDA up 25% to GBP1.5m (2013: GBP1.2m) -- Basic EPS up 85% to 1.91p (2013: 1.03p) -- Interim dividend of 0.585p per share (2013: 0.36p), an increase of 63% -- Cash generative, with net cash at period end of GBP2.9m (2013: GBP1.5m) | rcturner2 | |
23/4/2015 20:34 | IC tip of the week They say earnings growth is being seriously undervalued. Buy. | jimmygee2 | |
22/4/2015 14:13 | Tristel @Tristeluk Visit our Belgian Distributor @EcomedServices exhibiting @VHIGcongres to learn about our new Tristel Trace System! | piedro | |
21/4/2015 15:44 | APAD, Interesting arguments. Are you implying that this is a dodgy and unreliable share? | piedro | |
18/4/2015 10:59 | I have an "increaase" price set at 70p, G. I think P's position, above, is emminently sensible. However, the trouble with small caps is that as soon as a view is accepted the price has moved, so one has to anticipate the position. The recovery trajectory finished in June last year and the share price has gone nowhere in particular since then. So, the next leg will be up or down depending on results. My view is that the management have proved themselves since exiting the endoscope market and that it is worth anticipating good results in the summer when the share price is at the bottom of its oscillation. This is with the caveat that I would limit the holding to 2% of my portfolio (nothing is above 10%). apad | apad | |
15/4/2015 19:35 | Tristel will be exhibiting at the Mello investor workshop event next week so you can meet the directors then www.melloevents.com/ | davidosh | |
15/4/2015 16:26 | Mach100, Re: the stickers I prefer to bathe my animals with shampoo + tick pouron And believe a healthy country life is better than living in a kennel. Cheers. | piedro | |
15/4/2015 16:16 | Good luck Gostevie63. I find the brokers EPS for Jun 2015 of 4.01-4.20p a bit advanced and prefer c.3.80p as more conservative, but if proved wrong will gladly accept that recovery has now become sustainable growth and a PE of 22 less risky. AIMHO, BWDIK | piedro | |
15/4/2015 15:43 | Greetings fellow Tristel holders. I bought-in today at 71.4p (including costs). Did my own research after reading THEwheeliedealer's blog last week and liked what I saw. | gostevie63 | |
15/4/2015 13:15 | How many stickers have you accumulated so far, Piedro? Bid has fallen to 69p now but hopefully we can move back up again in short order. Might be due to the popularity of the above prizes :P | mach100 | |
14/4/2015 14:16 | A give-away ... Anisteluk @anisteluk Heard about Anistel's #Loyalty Scheme...?Collect stickers on caps of Anistel 5L Surface Disinfectant to claim prizes! | piedro | |
12/4/2015 09:17 | I found this before the advert above and can recommend it. apad | apad | |
11/4/2015 21:12 | Hi all, I have a few TSTL and did a detailed Blog on them this week with Overview, Risks, Valuation, Targets etc. and some Charts - check it out here: I expect to be holding these for a good few years and the upside here looks pretty attractive. Seems like a business that is really on a Roll.. cheers, WheelieD | thewheeliedealer | |
10/4/2015 15:05 | Anisteluk @anisteluk "Another great day at Anistel Stand 607!" | piedro | |
09/4/2015 15:05 | BSAVA2015 - Stand 607 | piedro | |
08/4/2015 09:53 | A new gimmick ... Pure Hold Hygiene Handle - a unique, revolutionary pull door handle that automatically dispenses sanitising gel The Pure Hold Hygiene Handle is ideal for use in food processing plants, hospitals, clean rooms and all staff/ public toilets to ensure that hand hygiene is enforced. .... - I expect Tristel to do one better than the competition | piedro | |
08/4/2015 09:44 | We're still awaiting confirmation of "sustainable recovery" and the 'Revolver' launch AIMO | piedro | |
08/4/2015 08:32 | *boing* here's hoping we break the sideways pattern with this one | rufio90210 | |
04/4/2015 20:28 | We have our Mello Workshops event just three weeks away and I am pleased to say that Tristel will have a stand at our event. There will be lots of investor educational workshops to attend and great speakers. If you are keen on small caps and quality companies where you will be able to meet the directors then you should come to the Mello investor workshops event as we will have at least 30 coming to Peterborough and we have just released the first list ...... | davidosh | |
02/4/2015 19:52 | It could easily go into the 60s, seen all sorts of funny share price movements over the years. Check out Amino Tech, which inexplicably dropped to 80p at one point, now about 140p. | rcturner2 | |
02/4/2015 14:19 | But maybe shorter than the wait for 69.875p? | effortless cool | |
02/4/2015 13:55 | Gonna be a long wait then | metier9 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions